bms 207940 has been researched along with fentanyl in 1 studies
| Studies (bms 207940) | Trials (bms 207940) | Recent Studies (post-2010) (bms 207940) | Studies (fentanyl) | Trials (fentanyl) | Recent Studies (post-2010) (fentanyl) |
|---|---|---|---|---|---|
| 6 | 0 | 0 | 15,288 | 4,310 | 4,483 |
| Protein | Taxonomy | bms 207940 (IC50) | fentanyl (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 6.5 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.6342 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0122 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.1888 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0122 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0058 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.3092 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 5.893 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 1.58 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0031 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.8197 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 4.973 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.354 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
1 review(s) available for bms 207940 and fentanyl
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |